Primary mediastinal B-cell lymphoma: a nationwide real-life retrospective study of first-line treatment approaches in Italy.
Not available.
We have 3 of 45 papers
We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.
Not the right person? Other researchers publish under this name.
Not available.
Chimeric Antigen Receptor (CAR) T-cell therapy targeting CD19 has demonstrated efficacy as salvage treatment for patients with relapsed/refractory (R/R) primary mediastinal B-cell lymphoma (PMBCL), however, a direct comparison between CAR T activity and other salvage treatments has not previously been performed. This s...
In AML patients receiving alloHSCT with PTCy, outcomes were largely similar regardless of whether CR1 was achieved after one or two-induction courses, with relapse incidence being higher in patients requiring 2 inductions.
We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.